Effect of @entity3371 on the cerebral circulation in XXXX .

@entity1 @entity712 @entity26 @entity3371 @entity551 @entity1779
Cerebral blood flow (CBF) was investigated in 8 @entity1 with @entity712 ( @entity712 ) (functional class III) and in twelve controls before and after administration of 6.25 mg and 25 mg @entity3371 , respectively. In four controls, CBF was measured by the intracarotid xenon-133 (133Xe) injection technique using stationary external detectors, while inhalation of 133Xe and single photon emission computer tomography was used in the remaining cases. In the control group, the cerebral metabolic rate for @entity26 was calculated from measurements of the arterio-venous @entity26 difference as well. Mean CBF was significantly (P less than 0.01) lower in the @entity1 with @entity712 as compared to our controls. Following @entity3371 administration the mean arterial blood pressure decreased in the @entity712 @entity1 , ranging from 5 to 40%. Three @entity1 showed decreases of blood pressure to values of 56, 65, and 76 mm Hg, but no symptoms of @entity1779 were elicited. CBF was unchanged after @entity3371 administration, even in the @entity1 showing a marked @entity551 . In the control group, the blood pressure, CBF and the cerebral metabolic rate for @entity26 remained essentially constant following @entity3371 administration. It is concluded that the cerebral circulation is well preserved during @entity3371 treatment of @entity712 . This might be explained by a shift of the lower limit of CBF autoregulation towards lower blood pressure levels.
